Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 17, Issue 7, 2010, Pages 1808-1815

  Weng, Chia Jui ^a   Hsieh, Yi Hsien ^b   Tsai, Chiung Man ^c   Chu, Yin Hung ^b   Ueng, Kwo Chang ^b,d   Liu, Yu Fan ^b   Yeh, Yuan Hung ^b,e   Su, Shih Chi ^f   Chen, Yi Chen ^b   Chen, Mu Kuan ^b,g,h   Yang, Shun Fa ^b,d  

^a TAINAN UNIVERSITY OF TECHNOLOGY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c Chest Hospital   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e Yang Ming Rehabilitation Clinic   (Taiwan)

^f TEXAS A AND M UNIVERSITY   (United States)

^g CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^h MINGDAO UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; INSULIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; IGFBP3 PROTEIN, HUMAN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; RISK FACTOR;

AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTOR, IGF TYPE 1; RECEPTOR, IGF TYPE 2; RISK FACTORS; SOMATOMEDINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3;

EID: 77954953292     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0904-8     Document Type: Article

References (45)

1. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191-211.
2. Department of Health, Republic of China. Health statistics: II. Vital statistics. Taipei: Department of Health, 2007.
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674-87.
4. Firpi RJ, Nelson DR. Viral hepatitis: manifestations and management strategy. Hematology Am Soc Hematol Educ Program. 2006;375-80.
5. Yano Y, Yamashita F, Kuwaki K, et al. Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II. Liver Int. 2006;26:789-795.
6. Akkiz H, Bayram S, Bekar A, et al. G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: Case-control study. Cancer Epidemiol. 2009 (in press).
7. Chang CC, Chen SC, Hsieh YH, et al. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin Chem Lab Med. 2009;47:412-18.
8. Liu JP, Baker J, Perkins AS, et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGFI) and type I IGF receptor (IGFIr). Cell 1993;75:59-72.
9. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505-18.
10. Gomes MV, Soares MR, Pasqualim-Neto A, Marcondes CR, Lôbo RB, Ramos ES. Association between birth weight, body mass index and IGF2/ApaI polymorphism. Growth Horm IGF Res. 2005;15:360-62.
11. LeRoith D, Roberts Jr. CT. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127-37.
12. LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995;16:143-63.
13. Chao W, D'Amore PA. IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 2008;19:111-20.
14. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov. 2008;6:821-33.
15. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol. 2008;4:591-602.
16. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:435-44.
17. Cheng I, Stram DO, Penney KL et al. Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. J Natl Cancer Inst. 2006;98:123-34. (Pubitemid 43159967)
18. Deming SL, Ren Z, Wen W, Shu XO, Cai Q, Gao YT, et al. Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat. 2007;104:309-19.
19. Kaku K, Osad H a, Seki K, Sekiya S. Insulin-like growth factor 2 (IGF2) and IGF2 receptor gene variants are associated with fetal growth. Acta Paediatrica. 2007;96:363-7.
20. Ho GY, Melman A, Liu SM, et al. Polymorphism of the insulin gene is associated with increased prostate cancer risk. Br J Cancer. 2003;88:263-9.
21. Rezgui D, Williams C, Savage SA, et al. Structure and function of the human Gly1619Arg polymorphism of M6P/IGF2R domain 11 implicated in IGF2 dependent growth. J Mol Endocrinol. 2009;42:341-56.
22. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 2005;16:421-39.
23. DaCosta SA, Schumaker LM, Ellis MJ. Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate? J Mammary Gland Biol Neoplasia. 2000;5:85-94.
24. Oates AJ, Schumaker LM, Jenkins SB, et al. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 1998;47:269-81.
25. Cohen P. Insulin-like growth factor binding protein-3: insulin-like growth factor independence comes of age. Endocrinology. 2006;147:2109-11.
26. Hoyo C, Grubber J, Demark-Wahnefried W, et al. Grade-specific prostate cancer associations of IGF1 (CA) 19 repeats and IGFBP3-202A/C in blacks and whites. J Natl Med Assoc. 2007;99:718-22.
27. Claeys GB, Sarma AV, Dunn RL, et al. INSPstI polymorphism and prostate cancer in African-American men. Prostate. 2005;65:83-7.
28. Centers for Disease Control, Taiwan, 2007. http://www.cdc.gov. tw.
29. Wu X, Yu H, Amos CI, Hong WK, Spitz MR. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst. 2000;92:737-43. (Pubitemid 30365534)
30. Hankinson L, Strohm O, Osterziel K, et al. Insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;352:489-99.
31. Stattin P, Rinaldi S, Biessy C, et al. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based non-screened cohort. J Clin Oncol. 2004;22:3104-12.
32. El Atiq F, Garrouste F, Remacle-Bonnet M, et al. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer. 1994;57:491-97.
33. Ma J, Pollak M, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91:628-9.
34. Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut. 2002;50:642-6.
35. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000;183:1-9.
36. Jacobs CI. A review of the role of insulin-like growth factor 2 in malignancy and its potential as a modifier of radiation sensitivity. Clin Oncol (R Coll Radiol). 2008;20:345-52.
37. Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem. 2000;275:28341-44.
38. Kotsinas A, Evangelou K, Sideridou M, et al. The 30 UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer. Cancer Lett. 2008;259:177-85.
39. Jang HS, Kang KM, Choi BO, Chai GY, Hong SC, Ha WS, et al. Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma. World J Gastroenterol. 2008;14:1394-8.
40. Ren Z, Cai Q, Shu XO, et al. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev. 2004;13:1290-5.
41. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab. 2001;86:1274-80.
42. Tsai MC, Kee KM, Chen YD, et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol. 2007;22:92-8.
43. Kumar M, Kumar R, Hissar SS, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol. 2007;22:1104-11.
44. Fuke H, Sugimoto K, Shiraki K, et al. Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization. Aliment Pharmacol Ther. 2008;27:1253-60.
45. Changchien CS, Chen CL, Yen YH, et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008;43:159-70.